5545-17-5 | N,N'-Diacetyl-l-cystine

Packsize	Purity	Availability	Price	Discounted Price
100mg	97%	in stock	$47.00	$33.00
250mg	98%	in stock	$62.00	$44.00
1g	≥90%	in stock	$94.00	$66.00
5g	97%	in stock	$365.00	$256.00
10g	95%	in stock	$667.00	$467.00
25g	95%	in stock	$1,319.00	$923.00

Description

• Catalog Number: AG24678
• Chemical Name: N,N'-Diacetyl-l-cystine
• CAS Number: 5545-17-5
• Molecular Formula: C10H16N2O6S2
• Molecular Weight: 324.3738
• MDL Number: MFCD00152053
• SMILES: OC(=O)[C@@H](NC(=O)C)CSSC[C@@H](C(=O)O)NC(=O)C

Computed Properties

• Complexity: 354
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 9
• XLogP3: -0.4

Literature

• The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism.

  Atherosclerosis 20080101

• N,N-diacetyl-L-cystine improves endothelial function in atherosclerotic Watanabe heritable hyperlipidaemic rabbits.

  Basic & clinical pharmacology & toxicology 20070101

• Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipopolysaccharide induced immunological liver failure in mice.

  Yao xue xue bao = Acta pharmaceutica Sinica 20041001

• The antiatherogenic effect of DiNAC: experimental findings supporting immunomodulation as a new treatment for atherosclerosis related diseases.

  Cardiovascular drug reviews 20030101

• Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?

  Expert opinion on investigational drugs 20020501

• N,N'-diacetyl-L-cystine (DiNAC), the disulphide dimer of N-acetylcysteine, inhibits atherosclerosis in WHHL rabbits: evidence for immunomodulatory agents as a new approach to prevent atherosclerosis.

  The Journal of pharmacology and experimental therapeutics 20011001

• Monitoring of the subtraction process in solid-phase representational difference analysis: characterization of a candidate drug.

  Gene 20010627